JAN 07, 2020 1:53 PM PST

"Good" T Cells Can Go "Bad," But in the Case of Cancer, That's A Good Thing

WRITTEN BY: Kara Marker

T cells may be able to reach their full potential in the fight against cancer with a little nudge. In 2010, scientists first observed CD4+ T cells transitioning from a regulatory role to a cytotoxic role, directly targeting and killing cancer cells as a result of immunotherapy. After this observation, the same team sought to identify the key mechanisms behind this transition. What molecular and cellular interactions are necessary to “nudge” CD4+ T cells in a more cytotoxic direction when survival against cancer is on the line?

T cells like CD4+ cells are included as ingredients in immunotherapy protocols because of their role in the immune response to threats against the body, including cancer and pathogens. Immunotherapy is an approach to cancer treatment that relies on boosting the body’s natural mechanisms for thwarting cancer, including optimizing the activity of immune system components like T cells. To reach their full potential, some T cells first need be equipped to recognize cells as cancerous when necessary.

A new study conducted in mice identified T cell growth factor interleukin (IL)-2 and transcription factor Blimp-1 as factors responsible for altering CD4+ T cells’ functional identity, triggering the change from regulatory to cytotoxic in the context of cancer.

Past research of IL-2 associates this growth factor with working alongside regulatory T cells to maintain self-tolerance, the immune practice of preventing immune cells from attacking the body’s own cells during the immune response. Blimp-1, also know as “B lymphocyte-induced maturation protein-1,” is linked to the “development and function of antibody-producing B cells,” an important part of the adaptive immune response.

With this information, researchers can optimize the way in which they recruit CD4+ T cells in immunotherapy approaches to treat cancer. Upon translating the results of the current study to cases of human immune interactions, researchers can develop novel custom cell therapies specifically targeting IL-2 and Blimp-1 in different contexts of cancer. Results from the present study have the potential to greatly improve the way scientists equip T cells to recognize cancerous cells for application of immunotherapy.

Sources: National Cancer Institute, Journal of Leukocyte Biology, University College London, Immunity

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAR 19, 2020
Infographics
MAR 19, 2020
All You Need to Know About Coronavirus (CoVID-19)
A new coronavirus, first identified in China in December 2019, has caused an outbreak of respiratory illness that was re ...
MAR 23, 2020
Drug Discovery & Development
MAR 23, 2020
Is Fast-Tracking Vaccines for Coronavirus Really Such a Good Idea?
Donald Trump has called on researchers to “slash red tape like nobody has even done it before” to accelerate ...
MAR 29, 2020
Cell & Molecular Biology
MAR 29, 2020
Learning More About Boosting Immunity in Older Adults
Older adults are more susceptible to infections and don't generate a robust immune response after a vaccination.
APR 02, 2020
Immunology
APR 02, 2020
Potential New COVID-19 Vaccine is Delivered by Patch
The coronavirus pandemic caused by SARS-CoV-2 is demanding the world's immediate attention.
APR 02, 2020
Immunology
APR 02, 2020
Transforming T Cells into Powerful Memory Cells That Target Cancer
New cancer treatments are now based on harnessing the power of the human body’s own immune cells to get the job do ...
JUN 10, 2020
Drug Discovery & Development
JUN 10, 2020
FDA Approves New Antibiotic for Hospital-Acquired Pneumonia
The US Food and Drug Administration (FDA) has approved Recarbrio, an antibiotic drug created by pharmaceutical company M ...
Loading Comments...